PRO-203 bispecific CD20xCD3 T cell engager for systemic sclerosis, severe lupus, lupus nephritis; oncology data showed 59% CR / 82% ORR in r/r NHL; rights from KeyMed Biosciences and InnoCare Pharma
No detailed funding rounds available.
Total known funding: